UrologyNews.net

Urology Xagena

Search results for "Metastatic prostate cancer"

Androgen deprivation therapy, which blocks steroid hormones called androgens, is used in around 50% of prostate cancer patients. It is recommended for locally advanced and metastatic prostate cancer. ...


Hormone therapy used to treat men with advanced prostate cancer is associated with an increased chance of developing various heart problems. Some choices of therapy appear, however, to be less risky t ...


In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy ( ADT ) was associated with a significantly increased risk of acute kidney injury, ...


Replacing carbohydrates and animal fat with vegetable fat may be associated with a lower risk of death in men with nonmetastatic prostate cancer. Nearly 2.5 million men currently live with prostate ...


Results from the phase III study of Triptorelin pamoate 11.25 mg ( Decapeptyl 3 months ) administered subcutaneously in patients with locally advanced or metastatic prostate cancer were presented at t ...


The results from the phase 2 TERRAIN trial of Enzalutamide ( Xtandi ) compared to Bicalutamide ( Casodex ) in metastatic castration-resistant prostate cancer ( CRPC ) are published in the Lancet Oncol ...


The results from the STRIVE trial of Enzalutamide ( Xtandi ) compared to Bicalutamide ( Casodex ) in men with castration-resistant prostate cancer ( CRPC ) are published in the Journal of Clinical Onc ...


In a phase III clinical trial, the hormone therapy Enzalutamide ( Xtandi ) extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation thera ...